Pharmacokinetic/Pharmacodynamic Analysis of Isavuconazole Against Aspergillus spp. and Candida spp. in Healthy Subjects and Patients With Hepatic or Renal Impairment by Monte Carlo Simulation

Journal of Clinical Pharmacology
Xiaowei ZhengPing Huang

Abstract

The aim of this pharmacokinetic/pharmacodynamic (PK/PD) study is to evaluate the efficacy of various isavuconazole dosing regimens for healthy individuals and patients with hepatic or renal impairment against Aspergillus spp. and Candida spp. Monte Carlo simulations were conducted using pharmacokinetic (PK) parameters and pharmacodynamics (PD) data to determine the probabilities of target attainment and cumulative fractions of response in terms of area under the concentration curve/minimum inhibition concentration (AUC/MIC) targets of isavuconazole. A clinically recommended dosage regimen of isavuconazole (200 mg qd) obtained high cumulative fraction of response values of > 90% for all subjects against A. fumigatus, A. flavus, A. nidulans, A. terreus, A. versicolor, C. parapsilosis and C. tropicalis. For patients with mild or moderate hepatic impairment, the dosage should be halved only when treating invasive fungal infections caused by C. albicans, C. parapsilosis or C. tropicalis. However, dose adjustment is unlikely to be required in mild to severe renal impairment patients because all cumulative fraction of response values were similar to those of comparing with healthy subjects. Notably, all isavuconazole dosing regimens w...Continue Reading

References

Aug 15, 2009·Expert Opinion on Investigational Drugs·Corrado Girmenia
Apr 26, 2012·Expert Opinion on Drug Metabolism & Toxicology·Joanne Livermore, William Hope
Sep 5, 2013·Antimicrobial Agents and Chemotherapy·Alexander J LepakDavid R Andes
Dec 10, 2014·Expert Review of Anti-infective Therapy·Seyedmojtaba SeyedmousaviJohan W Mouton
Mar 11, 2015·Antimicrobial Agents and Chemotherapy·Seyedmojtaba SeyedmousaviJohan W Mouton
May 6, 2015·The Annals of Pharmacotherapy·Natasha N Pettit, Peggy L Carver
May 23, 2015·Future Microbiology·Michelle R Ananda-Rajah, Dimitrios Kontoyiannis
Jun 24, 2015·Expert Opinion on Pharmacotherapy·Maria N Chitasombat, Dimitrios P Kontoyiannis
Oct 28, 2015·Antimicrobial Agents and Chemotherapy·Helen BoxWilliam W Hope
Mar 10, 2016·Antimicrobial Agents and Chemotherapy·Amit DesaiRobert Townsend
Mar 4, 2017·Intensive Care Medicine·Matteo BassettiOliver A Cornely
Mar 9, 2017·European Journal of Clinical Pharmacology·Robert W TownsendAmit V Desai

❮ Previous
Next ❯

Citations

Nov 27, 2019·Antimicrobial Agents and Chemotherapy·Xuemei WuM Hong Nguyen
Dec 14, 2018·Journal of Fungi·Nikolaos Spernovasilis, Diamantis P Kofteridis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Aspergillosis (ASM)

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Aspergillosis

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.